AVBP (ArriVent BioPharma) Additional Paid-In Capital : $496.20 Mil(As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Additional Paid-In Capital?

ArriVent BioPharma's quarterly additional paid-in capital declined from Jun. 2024 ($493.79 Mil) to Sep. 2024 ($4.65 Mil) but then increased from Sep. 2024 ($4.65 Mil) to Dec. 2024 ($496.20 Mil).

ArriVent BioPharma's annual additional paid-in capital increased from Dec. 2022 ($3.40 Mil) to Dec. 2023 ($4.65 Mil) and increased from Dec. 2023 ($4.65 Mil) to Dec. 2024 ($496.20 Mil).

ArriVent BioPharma Additional Paid-In Capital Historical Data

The historical data trend for ArriVent BioPharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Additional Paid-In Capital Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

2.96

3.40

4.65

496.20

ArriVent BioPharma Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial						4.65	492.98	493.79	4.65	496.20

ArriVent BioPharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

ArriVent BioPharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073

Website

https://www.arrivent.com

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.